Poster Presentation at AMP 2016 Annual Meeting
Introduction: The 2013 CAP/IASLC/AMP joint guidelines call for EGFR/ALK testing in all patients (pts) with stage IV NSCLC with adenocarcinoma components. In 2014 the NCCN guidelines added emerging actionable targets. The adoption rate of guidelines in community practice has not been fully explored for these two sets of guideline endorsements.
Authors: P. Bhattacharyya, A. Dalal, T. Wu, K.W. Culver, K. Choi, R. Pe Benito, Y. Sarpong, E. Brzostowski , A. Maresca, K. Vermilyea, M. Smith, W. Jappe, J. Covington, S. Goldberg,Hackensack University Medical Center, Hackensack, NJ; Novartis, East Hanover, NJ; COTA, New York, NY.